These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25316810)

  • 1. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
    Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
    Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
    Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
    J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.
    Goff L; Summers K; Iqbal S; Kuhlmann J; Kunz M; Louton T; Hagenbeek A; Morschhauser F; Putz B; Lister A; Rohatiner A
    J Clin Oncol; 2009 Dec; 27(36):6094-100. PubMed ID: 19858392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
    Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
    Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
    Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
    Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma].
    Belada D; Smolej L; Stepánková P; Beránek M; Dvoráková D; Bukac J; Malý J
    Vnitr Lek; 2007 Oct; 53(10):1057-63. PubMed ID: 18072430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
    Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
    Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice.
    Janikova A; Mareckova A; Dvorakova D; Bortlicek Z; Tichy B; Navratil M; Kral Z; Pospisilova S; Mayer J
    Exp Hematol; 2012 Jul; 40(7):528-539.e4. PubMed ID: 22381682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
    Rambaldi A; Lazzari M; Manzoni C; Carlotti E; Arcaini L; Baccarani M; Barbui T; Bernasconi C; Dastoli G; Fuga G; Gamba E; Gargantini L; Gattei V; Lauria F; Lazzarino M; Mandelli F; Morra E; Pulsoni A; Ribersani M; Rossi-Ferrini PL; Rupolo M; Tura S; Zagonel V; Zaja F; Zinzani P; Reato G; Foa R
    Blood; 2002 Feb; 99(3):856-62. PubMed ID: 11806987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
    Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL
    Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
    Ladetto M; Lobetti-Bodoni C; Mantoan B; Ceccarelli M; Boccomini C; Genuardi E; Chiappella A; Baldini L; Rossi G; Pulsoni A; Di Raimondo F; Rigacci L; Pinto A; Galimberti S; Bari A; Rota-Scalabrini D; Ferrari A; Zaja F; Gallamini A; Specchia G; Musto P; Rossi FG; Gamba E; Evangelista A; Vitolo U;
    Blood; 2013 Nov; 122(23):3759-66. PubMed ID: 24085766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma].
    Chen ZY; Zhou XY; Zhang TM; Hong XN; Yin JL; Hu XC; Shi DR
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):183-8. PubMed ID: 19615255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
    Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
    Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
    Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
    Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Cavalli M; De Novi LA; Della Starza I; Cappelli LV; Nunes V; Pulsoni A; Del Giudice I; Guarini A; Foà R
    Br J Haematol; 2017 May; 177(4):588-596. PubMed ID: 28419517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High molecular response rate and clinical correlation in patients with follicular lymphoma treated with cyclophosphamide-vincristine-prednisone plus interferon alpha 2b.
    Fernández-Ruiz E; Cabrerizo M; Ortega M; Blas C; Llamas P; Santos-Roncero M; Nieto S; Acevedo A; Pérez G; Nicolás C; Fernández-Rañada JM; Arranz R
    Clin Cancer Res; 2003 Jul; 9(7):2497-503. PubMed ID: 12855623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.